Bevacizumab (Avastin)
Immunotherapy · Approved since 2004
Description
Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A) and serves as a cornerstone anti-angiogenic therapy in colorectal cancer treatment. It is approved for first-line treatment of metastatic colorectal cancer in combination with fluoropyrimidine-based chemotherapy regimens such as FOLFOX or FOLFIRI. The drug is used across different molecular subtypes of CRC including microsatellite stable (MSS) and microsatellite instability-high (MSI-H) tumors, and regardless of KRAS, NRAS, or BRAF mutation status. Bevacizumab is also employed in second-line metastatic settings and is being combined with newer immunotherapy agents in pMMR/MSS colorectal cancer.
Mechanism of Action
Bevacizumab es un anticuerpo monoclonal anti-VEGF-A que inhibe la angiogenesis tumoral, normalizando la vasculatura y mejorando la entrega de quimioterapia.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Avastin |
| Category | Immunotherapy |
 Status | FDA Approved |
 EMA Status | EMA Approved |
 Spain Access | Funded by SNS approved in CRC |
| Administration | IV |
| Year Approved | 2004 |
| Clinical Trials | 493 |
Regimens with this Drug
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.